心脏再同步治疗起搏器召回前后的结局分析
该单中心回顾性病例系列纳入2003年5月至2011年1月在明尼阿波利斯心脏研究所植入某心脏再同步治疗起搏器的448例患者中的90例,该起搏器于2015年11月被召回。2015年观察到90例中5例因电池或导线连接缺陷导致起搏停止而出现晕厥。对2008年1月至2018年12月MAUDE数据库的分析显示,召回前电池故障相关严重不良事件包括1例死亡、1例心脏骤停、5例晕厥发作和6例心力衰竭加重;另有3例召回前晕厥由导线连接缺陷引起。制造商和FDA在发布召回前19个月已知晓电池和导线连接缺陷,但导线连接问题未纳入通告,医师未被告知程控检查可能导致起搏丢失。作者认为召回延迟且后续沟通未包含安全有效管理所需全部关键信息。
要点
- 90例植入该起搏器的患者中,2015年观察到5例因电池或导线连接缺陷导致起搏停止而出现晕厥。
- MAUDE数据库分析显示,召回前电池故障相关严重不良事件包括1例死亡、1例心脏骤停、5例晕厥发作和6例心力衰竭加重。
- 另有3例召回前晕厥由导线连接缺陷引起。
- 制造商和FDA在发布召回前19个月已知晓电池和导线连接缺陷,但导线连接问题未纳入通告。
- 医师未被告知程控检查可能导致起搏丢失,FDA将召回归类为II类而非更关键的I类。
适用人群与场景
- 2003年5月至2011年1月在明尼阿波利斯心脏研究所植入某心脏再同步治疗起搏器的448例患者中的90例(单中心回顾性病例系列)。
- 90例中37例(41%)为男性,植入时中位年龄71.3岁(四分位距66.1-78.2岁)。
红旗征与不能漏的情况
- 起搏器因电池或导线连接缺陷停止起搏可导致晕厥,召回前已有5例因此出现晕厥。
- 电池故障相关严重不良事件包括1例死亡、1例心脏骤停、5例晕厥发作和6例心力衰竭加重。
- 导线连接缺陷导致3例召回前晕厥事件。
- 程控检查可能导致起搏丢失,医师未被告知此风险。
研究设计与关键结果
- 研究类型为单中心回顾性病例系列,纳入90例植入某心脏再同步治疗起搏器的患者,该起搏器于2015年11月被召回。
- 2015年观察期间,90例中5例因电池或导线连接缺陷导致起搏停止而出现晕厥。
- MAUDE数据库2008年1月至2018年12月数据分析显示,召回前电池故障相关严重不良事件包括1例死亡、1例心脏骤停、5例晕厥发作和6例心力衰竭加重;另有3例召回前晕厥由导线连接缺陷引起。
- 制造商和FDA在发布召回前19个月已知晓电池和导线连接缺陷,但导线连接问题未纳入通告,医师未被告知程控检查可能导致起搏丢失。
- FDA将召回归类为II类而非更关键的I类。
证据类型、等级与局限
- 证据类型:单中心回顾性病例系列,纳入90例患者,并分析MAUDE数据库2008年1月至2018年12月的返回产品报告。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些发现应促使对医疗器械行业和FDA管理未来医疗器械召回的方式进行改革。
- 原文未据此给出针对急诊或ICU的具体推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Timely and complete disclosure of medical device defects is necessary to manage patient care safely and effectively.
OBJECTIVES: To determine if the manufacturer's recommendations following the recall of a medical device were timely and complete, the follow-up information and data provided to patients and physicians were adequate for managing patient care, and the actions taken by the US Food and Drug Administration (FDA) regarding the recall were appropriate.
DESIGN, SETTING, AND PARTICIPANTS: This single-center retrospective case series included 90 of 448 patients who were implanted with a cardiac resynchronization therapy pacemaker at the Minneapolis Heart Institute from May 2003 through January 2011; this pacemaker was recalled in November 2015. In addition, returned product reports submitted by the manufacturer to the FDA via the Manufacturer and User Facility Device Experience (MAUDE) database from January 2008 through December 2018 were analyzed.
MAIN OUTCOMES AND MEASURES: Clinical outcomes were serious adverse clinical events that occurred before and after the November 2015 recall notifying physicians and patients that the device's battery could fail unexpectedly because of high internal impedance. Technical outcomes were signs and causes of failure.
RESULTS: Five of 90 patients observed during 2015 experienced syncope when their pacemakers stopped pacing owing to battery or wire connection defects prior to the recall. Of the 90 patients, 37 (41%) were men, and the median (interquartile range) age at implantation was 71.3 (66.1-78.2) years. Analysis of the MAUDE data revealed that battery failures prior to the recall were associated with serious adverse events that included 1 death, 1 cardiac arrest, 5 syncopal attacks, and 6 heart failure exacerbations; 3 additional prerecall syncopal events were caused by wire connection defects. The manufacturer and the FDA were aware of the battery and wire connection defects for 19 months before issuing the recall, yet the wire connection problem was not included in the advisory and physicians were not informed that interrogating the pacemaker could result in loss of pacing. The FDA classified the recall as class II rather than the more critical class I.
CONCLUSIONS AND RELEVANCE: This case series study of patients implanted with a defective pacemaker found that the pacemaker recall was delayed and that subsequent communications did not include all critical information needed for safe and effective patient care. These findings should prompt reforms in how the medical device industry and the FDA manage future medical device recalls.
参考来源
- Sengupta J, Storey K, Casey S, et al. Outcomes Before and After the Recall of a Heart Failure Pacemaker. JAMA Intern Med. 2020. PMID: 31860011. doi:10.1001/jamainternmed.2019.5171
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。